Catalyst Wire Dossier Catalyst Wire Dossier

Rebastinib

rebastinib · Deciphera Pharmaceuticals, LLC
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Rebastinib, covering 2024-12-27 to 2024-12-27. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

See pricing